- Home
- ISPR vs CYBN Comparison
ISPR vs CYBN Comparison
Compare ISPR & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- CYBN
- Stock Information
- Founded
- ISPR 2019
- CYBN 2019
- Country
- ISPR United States
- CYBN Canada
- Employees
- ISPR N/A
- CYBN N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- CYBN Pharmaceuticals and Biotechnology
- Sector
- ISPR Health Care
- CYBN Health Care
- Exchange
- ISPR Nasdaq
- CYBN Nasdaq
- Market Cap
- ISPR 152.0M
- CYBN 178.7M
- IPO Year
- ISPR 2023
- CYBN N/A
- Fundamental
- Price
- ISPR $2.74
- CYBN $7.69
- Analyst Decision
- ISPR Strong Buy
- CYBN Strong Buy
- Analyst Count
- ISPR 2
- CYBN 4
- Target Price
- ISPR $10.00
- CYBN $85.00
- AVG Volume (30 Days)
- ISPR 51.3K
- CYBN 426.5K
- Earning Date
- ISPR 09-10-2025
- CYBN 08-12-2025
- Dividend Yield
- ISPR N/A
- CYBN N/A
- EPS Growth
- ISPR N/A
- CYBN N/A
- EPS
- ISPR N/A
- CYBN N/A
- Revenue
- ISPR $144,700,345.00
- CYBN N/A
- Revenue This Year
- ISPR N/A
- CYBN N/A
- Revenue Next Year
- ISPR $35.39
- CYBN N/A
- P/E Ratio
- ISPR N/A
- CYBN N/A
- Revenue Growth
- ISPR N/A
- CYBN N/A
- 52 Week Low
- ISPR $2.09
- CYBN $4.81
- 52 Week High
- ISPR $7.79
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- ISPR 45.91
- CYBN 48.21
- Support Level
- ISPR $2.92
- CYBN $7.26
- Resistance Level
- ISPR $3.04
- CYBN $8.18
- Average True Range (ATR)
- ISPR 0.16
- CYBN 0.44
- MACD
- ISPR -0.02
- CYBN -0.04
- Stochastic Oscillator
- ISPR 7.14
- CYBN 27.22
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.